CE2025-10-28T11:47:34
Approval provides continuity of care into adulthood for patients with neurofibromatosis type 1 (NF1) using Koselugo (selumetinib) to manage symptoms.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-07-13T07:00:00
Sponsored by Thermo Fisher Scientific
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-06-30T10:37:00
Sponsored by Bruker (SciY), European Pharmaceutical Review
2026-05-22T14:48:00
Sponsored by CPhI
Site powered by Webvision Cloud